Vantage logo

Sobi strikes again

CTI Biopharma sees an unlikely end to its 32-year rollercoaster existence.

Vantage logo

Abbvie takes its Treg cue

The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.